Management of Tachycardia in Patients on Lorazepam

Evaluation and Treatment

• The American College of Cardiology recommends determining the type of tachycardia through ECG evaluation to distinguish between supraventricular (SVT) or ventricular in origin 1, 2
• The American College of Cardiology suggests looking for P-wave morphology and relationship to QRS complexes to distinguish between focal atrial tachycardia (AT), multifocal atrial tachycardia (MAT), or other SVT mechanisms 1
• Intravenous beta blockers (such as metoprolol) are recommended for rate control in most forms of SVT, particularly effective for controlling ventricular rate in MAT, according to the American College of Cardiology 1, 2, 3
• Intravenous calcium channel blockers (such as verapamil or diltiazem) are equally effective first-line options for rate control in SVT, with verapamil showing efficacy in converting MAT in some patients, as per the American College of Cardiology and Circulation 1, 3, 4

Second-Line and Long-Term Management

• The American College of Cardiology recommends considering intravenous amiodarone for persistent tachycardia, which can be effective through beta-receptor and calcium channel blockade 5, 6
• Adenosine can be useful for diagnostic purposes and may terminate some forms of SVT, particularly effective for AVNRT and triggered forms of focal AT, according to the American College of Cardiology and Circulation 3, 4
• Oral metoprolol is reasonable for ongoing management of recurrent symptomatic MAT, and oral verapamil or diltiazem is reasonable for long-term management of MAT and other SVTs, as per the American College of Cardiology and Circulation 1, 2

Special Considerations and Monitoring

• Underlying conditions such as pulmonary disease, coronary disease, or valvular heart disease should be addressed, and electrolyte abnormalities, particularly hypomagnesemia, should be corrected, according to the American College of Cardiology 1
• Monitoring for conduction abnormalities and hypotension during treatment is crucial, and beta blockers should be avoided in patients with severe bronchospastic pulmonary disease, while calcium channel blockers should be avoided in patients with decompensated heart failure, as recommended by the American College of Cardiology 1